Scribd Logo
Upload

Welcome to Scribd!

  • 11 views

    Management of Community

    Uploaded by

    Trixie Anne Gamotin
    Community-acquired pneumonia is diagnosed clinically and via chest imaging showing lung infiltrates. Initial evaluation determines the need for hospitalization or outpatient management using severity scores. Selected diagnostic testing is recommended for severe inpatients but rarely useful for outpatients. Outpatients should receive a macrolide or doxycycline initially, or a respiratory fluoroquinolone if high-risk. Inpatients receive a respiratory fluoroquinolone or beta-lactam plus macrolide unless intensive care is needed, then broader coverage is used. Guidelines have improved outcomes, and vaccination prevents community-acquired pneumonia.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd

    Management of Community

    Uploaded by

    Trixie Anne Gamotin
    11 views1 page
    Community-acquired pneumonia is diagnosed clinically and via chest imaging showing lung infiltrates. Initial evaluation determines the need for hospitalization or outpatient management using severity scores. Selected diagnostic testing is recommended for severe inpatients but rarely useful for outpatients. Outpatients should receive a macrolide or doxycycline initially, or a respiratory fluoroquinolone if high-risk. Inpatients receive a respiratory fluoroquinolone or beta-lactam plus macrolide unless intensive care is needed, then broader coverage is used. Guidelines have improved outcomes, and vaccination prevents community-acquired pneumonia.

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Community-acquired pneumonia is diagnosed clinically and via chest imaging showing lung infiltrates. Initial evaluation determines the need for hospitalization or outpatient management using severity scores. Selected diagnostic testing is recommended for severe inpatients but rarely useful for outpatients. Outpatients should receive a macrolide or doxycycline initially, or a respiratory fluoroquinolone if high-risk. Inpatients receive a respiratory fluoroquinolone or beta-lactam plus macrolide unless intensive care is needed, then broader coverage is used. Guidelines have improved outcomes, and vaccination prevents community-acquired pneumonia.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    11 views1 page

    Management of Community

    Uploaded by

    Trixie Anne Gamotin
    Community-acquired pneumonia is diagnosed clinically and via chest imaging showing lung infiltrates. Initial evaluation determines the need for hospitalization or outpatient management using severity scores. Selected diagnostic testing is recommended for severe inpatients but rarely useful for outpatients. Outpatients should receive a macrolide or doxycycline initially, or a respiratory fluoroquinolone if high-risk. Inpatients receive a respiratory fluoroquinolone or beta-lactam plus macrolide unless intensive care is needed, then broader coverage is used. Guidelines have improved outcomes, and vaccination prevents community-acquired pneumonia.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 1

    Management of Community-Acquired Pneumonia in Adults

    Community-acquired pneumonia is diagnosed by clinical features (e.g., cough, fever, pleuritic chest pain) and by lung imaging, usually an infiltrate seen on chest radiography. Initial evaluation should determine the need for hospitalization versus outpatient management using validated mortality or severity prediction scores. Selected diagnostic laboratory testing, such as sputum and blood cultures, is indicated for inpatients with severe illness but is rarely useful for outpatients. Initial outpatient therapy should include a macrolide or doxycycline. For outpatients with comorbidities or who have used antibiotics within the previous three months, a respiratory fluoroquinolone (levofloxacin, gemifloxacin, or moxifloxacin), or an oral beta-lactam antibiotic plus a macrolide should be used. Inpatients not admitted to an intensive care unit should receive a respiratory fluoroquinolone, or a beta-lactam antibiotic plus a macrolide. Patients with severe community-acquired pneumonia or who are admitted to the intensive care unit should be treated with a beta-lactam antibiotic, plus azithromycin or a respiratory fluoroquinolone. Those with risk factors for Pseudomonas should be treated with a beta-lactam antibiotic (piperacillin/tazobactam, imipenem/cilastatin, meropenem, doripenem, or cefepime), plus an aminoglycoside and azithromycin or an antipseudomonal fluoroquinolone (levofloxacin or ciprofloxacin). Those with risk factors for methicillinresistant Staphylococcus aureus should be given vancomycin or linezolid. Hospitalized patients may be switched from intravenous to oral antibiotics after they have clinical improvement and are able to tolerate oral medications, typically in the first three days. Adherence to the Infectious Diseases Society of America/American Thoracic Society guidelines for the management of community-acquired pneumonia has been shown to improve patient outcomes. Physicians should promote pneumococcal and influenza vaccination as a means to prevent community-acquired pneumonia and pneumococcal bacteremia.

    You might also like